AZNAstraZenecaSigning up patients
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 675 (planned)
- Started
- Apr 11, 2024
- Main results expected
- Dec 28, 2029
- Fully finished
- Dec 28, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) in TROP2 biomarker positive participants.
Measured over: Approximately 4 years
Overall Survival (OS) in TROP2 biomarker positive participants.
Measured over: Approximately 6 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06357533 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC